TEL AVIV, Israel, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD) (the "Company"), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, announced today that an overview of the Company's business strategy will be given by Alcobra's Chief Executive Officer, Dr. Yaron Daniely, at the 25th Annual Piper Jaffray Healthcare Conference, being held at the New York Palace Hotel in New York City on December 3-4, 2013. The Alcobra presentation is on Wednesday, December 4 at 3:00pm Eastern Time.
A live webcast of Alcobra's presentation will be available at www.alcobra-pharma.com.
About Alcobra Ltd.
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MG01CI, to treat cognitive dysfunctions including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MG01CI has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
CONTACT: Michael Rice
LifeSci Advisors, LLC
646-597-6979
